Health & Fitness
Wed, July 25, 2012Tue, July 24, 2012Mon, July 23, 2012Sun, July 22, 2012Sat, July 21, 2012Fri, July 20, 2012Thu, July 19, 2012Wed, July 18, 2012Tue, July 17, 2012Mon, July 16, 2012Fri, July 13, 2012Thu, July 12, 2012Wed, July 11, 2012Tue, July 10, 2012Mon, July 9, 2012Fri, July 6, 2012Thu, July 5, 2012Wed, July 4, 2012Tue, July 3, 2012Mon, July 2, 2012Sun, July 1, 2012Fri, June 29, 2012Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
//health-fitness.news-articles.net/content/2012/ .. conference-call-and-webcast-on-july-25-2012.html
Published in Health and Fitness on Wednesday, July 11th 2012 at 6:38 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host... -- TARRYTOWN, N.Y., July 11, 2012 /PRNewswire/ --
Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
TARRYTOWN, N.Y., July 11, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)today announced that it will report its second quarter 2012 financial and operating results on Wednesday, July 25, 2012, before the U.S. financial markets open. The Company will host a conference call at 8:30 AM EDT that day.
Live audio of the conference call will be webcast online simultaneously. A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at [ www.regeneron.com ]. A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products in the United States, EYLEA® (aflibercept) Injection and ARCALYST® (rilonacept) Injection for Subcutaneous Use. Regeneron has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for EYLEA and ARCALYST and for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion. Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at [ www.regeneron.com ].
Contact Information:
Manisha Narasimhan, Ph.D. | Peter Dworkin |
Investor Relations | Corporate Communications |
914-847-5126 | 914.847.7640 |
SOURCE Regeneron Pharmaceuticals, Inc.
[ Back to top ]
RELATED LINKS
[ http://www.regeneron.com ]
